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SYMPOSIU:rv1: WORKSHOP 01'-J 
INHERITED BREAST CANCER IN 
JEWISH WOMEN: ETHICAL, 
LEGAL, AND SOCIAL 
IMPLICATIONS 
INTRODUCTION 
ON APRIL 26, 1996, the Law-Medicine Center and the 
Center for Biomedical Ethics at Case Western Reserve Univer-
sity held the first nati9nal workshop on the ethical, legal, and 
social implications associated with recent discoveries linking 
the BRCAI breast cancer gene to a specific population, that of 
Ashkenazic Jewish women. The idea for this workshop origi-
nated with Tom Murray, Director of the Center for Biomedical 
Ethics at the School of Medicii"1e; Eric Juengst, the first direc-
tor of the ELSI program at NIH and now a professor at the 
School of Medicine, and myself. The three of us also served as 
moderators during the workshop. We wish to thank the Leon-
ard and Harvey Krieger President's Endowment Fund for its 
generous support, without which this program would not have 
been possible. 
In 1995, researchers identified a gene - BRCAI -
which appears to be associated with an elevated risk of breast 
cancer in some women. Initially, there was little interest in 
screening women for the BRCAl gene because it had many 
mutations, each one of which would have to be tested for indi-
vidually, but no single one of which was prevalent in a signifi-
cant number of breast cancer patients. Later, researchers an-
nounced that one BRCAl mutation is associated with breast 
cancer that affects one percent of all Ashkenazic Jewish wom-
en, and accounts for almost forty percent of the breast cancer 
cases in this population. 
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The possibility of population-based genetic screening for 
this mutation raises a number of. ethical, legal, . and social is-
sues. In-depth discussion of these issues at the CWRtJ work-
shop provided significant insights· for religipus and. cominunity 
leaders, public hetilth ·officials, clinicians and genetic counsel-
lors, am~ public policy analysts. The results of the workshop 
will be of further significance for ethnically based genetic 
screening programs in general, SL'lCe it is expected that, in the 
future, researchers will discover many additional genetic muta-
tions associated with disorders within specific ethnic groups. 
The workshop was an informal exchange among invited 
experts in a variety of disciplines in a rapidly developing area. 
The discussion focused on seven papers that are being pub-
lished in this symposium volume. An account of the workshop, 
prepared by Pulitzer Prize winning journalist B.D. Colen, has 
appeared in the newsletters of the Center for Biomedical Ethics 
and the Law-Medicine Center. 
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